Visual Overview
Abstract
Voltage-gated sodium (NaV) channels are intimately involved in the generation and transmission of action potentials, and dysfunction of these channels may contribute to nervous system diseases, such as epilepsy, neuropathic pain, psychosis, autism, and cardiac arrhythmia. Many venom peptides selectively act on NaV channels. These include conotoxins, which are neurotoxins secreted by cone snails for prey capture or self-defense but which are also valuable pharmacological tools for the identification and/or treatment of human diseases. Typically, conotoxins contain two or three disulfide bonds, and these internal crossbraces contribute to conotoxins having compact, well defined structures and high stability. Of the conotoxins containing three disulfide bonds, some selectively target mammalian NaV channels and can block, stimulate, or modulate these channels. Such conotoxins have great potential to serve as pharmacological tools for studying the functions and characteristics of NaV channels or as drug leads for neurologic diseases related to NaV channels. Accordingly, discovering or designing conotoxins targeting NaV channels with high potency and selectivity is important. The amino acid sequences, disulfide bond connectivity, and three-dimensional structures are key factors that affect the biological activity of conotoxins, and targeted synthetic modifications of conotoxins can greatly improve their activity and selectivity. This review examines NaV channel–targeted conotoxins, focusing on their structures, activities, and designed modifications, with a view toward expanding their applications.
Significance Statement NaV channels are crucial in various neurologic diseases. Some conotoxins selectively target NaV channels, causing either blockade or activation, thus enabling their use as pharmacological tools for studying the channels’ characteristics and functions. Conotoxins also have promising potential to be developed as drug leads. The disulfide bonds in these peptides are important for stabilizing their structures, thus leading to enhanced specificity and potency. Together, conotoxins targeting NaV channels have both immediate research value and promising future application prospects.
Footnotes
- Received September 27, 2023.
- Revision received June 17, 2024.
- Accepted June 18, 2024.
This work was supported in part by the National Natural Science Foundation of China [Grant 82173736], Guangxi Science and Technology Base & Talents Fund [Grant GUIKE AD22035948], Major Intergovernmental Joint Research Project of National Key R & D Program of China [Grant 2022YFE0132700], Major International Joint Research Project of National Natural Science Foundation of China [Grant 82320108019], National Natural Science Foundation of China [Grants 42376112 and 82360698], and the 111 Project [Grant D20010] as well as National Institutes of Health National Institute of General Medical Sciences [Grant R35 GM136430] (to J.M.M.) and an NHMRC Investigator Grant [GNT2009564] (to D.J.C.). Work in D.J.C.’s laboratory is supported by the Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science [Grant CE200100012].
No author has an actual or perceived conflict of interest with the contents of this article.
- Copyright © 2024 by The American Society for Pharmacology and Experimental Therapeutics
PharmRev articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|